Return to homepagePandemic Pact

Development platforms for biosafe vaccines against SARS-CoV-2

  • Funded by National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)
  • Total publications:0 publications

Grant number: COV20_00237

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    National Institute of Health Carlos III [El Instituto de Salud Carlos III] (ISCIII)

  • Principal Investigator

    David Escors Murugarren

  • Research Location

    Spain

  • Lead Research Institution

    FUNDACION MIGUEL SERVET-NAVARRABIOMED

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

A biosafe vaccine engineering platform against SARS-CoV-2 will be established, including three production procedures. The first will use human cells secreting virus-like particles (VLPs), through the constitutive expression of the S, M and E proteins of SARS-CoV-2. The second will use baculoviral vectors for the expression of these genes on a large scale and to compare the production of VLPs. The third will be based on the production of non-replicative and non-integrative lentiviral particles, pseudotyped with the SARS-CoV-2 protein S and expressing the rest of the structural proteins. These particles will deliver the B and T epitopes to the immune system in a VLP format. BIRB796 will be incorporated into vaccine preparations to enhance the human T response, since it is a p38 MAPK inhibitor approved for human use and has anti-senescent properties in lymphocytes.